Proactive’s Post

📢 Creo Medical Group plc (#CREO) provides a trading update for the year ended 31 December 2023, including an overview of its commercial and clinical progress. ��� New products support strong growth and accelerate commercial momentum of Creo's core technology 📈 Double digit Group revenue growth and ongoing cost control 💰 The Company expects to report growth in Group revenues of 13%, from £27.2m in FY22 to £30.8m in FY23. ⬆ Core technology sales and Kamaptive licensing income increased to £4.0m (FY22 £2.3m) with core technology sales increasing c. 2.5x. 🗺 Speedboat® UltraSlim has been used successfully in procedures in the UK, USA, LATAM and APAC 🔗 https://lnkd.in/e-EAR2EH

Have any complex catheters. We got the solution

I found this stock forecast online for Avita Medical(RCEL) Long-Term AVITA Medical, Inc. Stock Price Predictions Based on the average yearly growth of the AVITA Medical, Inc. stock in the last 10 years. Using the same basis, coincodex estimated the stock value at $354.30 by the year 2031 which is roughly at 2400% increase from the current stock price of around $14.00. I sure hope they are close.

1st day of the Advanced Process Validation for Medical Devices Masterclass by Dr. Felix Kern is currently underway! Glad to have professionals from leading medical device manufacturers such as The Surgical Company PTM, Hollister Incorporated, Cook Medical on board! 2 exciting days of learning and networking ahead! #ProcessValidation #MedicalDevices #RegulatoryAffairs #CombinationDevices #RiskManagement #Keynotive

In an article published by Law360, partners Justin Gillett and Paul Stewart discuss the Federal Circuit’s recent decision in Axonics Inc. v. Medtronic Inc. “They argue that the case brings some clarity to inter partes review petitioners’ ability to respond to new claim constructions proposed after an IPR is instituted.”   Read more and access the full article here: https://lnkd.in/gVr8H65f   #KnobbeMartens #Knobbe #IPLaw

Being a spine rep is happy hours, president’s club trips, steak dinners and high fives right? Nope. More often it something more like this. This is me digging myself out of 2 ft of snow at 5:30am to make it to a first am case that will likely cancel or at least delay. As the spine rep…you have to be the constant…..not the company you carry, not the hospital staff, YOU, YOU have to be the constant. The company highfiving you right now will likely send another rep to call on your doctor within the next 3 years. YOU ARE YOUR BRAND. Follow guys like Matthew Ray Scott Darkwater Consulting Jameil ‘Jay’ Pendleton™ Gary Vaynerchuk Simon Sinek Build/protect your brand from your current business partner (company). If the company is forward thinking, they will support your brand to wisely build their own. Cheers to those few companies in spine who have the longterm vision of cobranding: Zavation Medical Products, LLC Kyocera Medical Technologies, Inc. Isto Biologics Cerapedics Inc. Centinel Spine Orthofix Premia Spine Intrinsic Therapeutics, Inc Sky Ridge Medical Center

Choosing partners and solvers that stick with it until we have success is right in my wheelhouse. There are many critical aspects of medical device manufacturing you need to think about when choosing the right adhesive. In this article, Solventum Premier Converter BDK will discuss the main considerations you must be aware of during the decision-making process. http://ms.spr.ly/6043YCyzZ

🌍 FebriDx® in Spain and Portugal   Lumos Diagnostics has announced it has signed an agreement with Henry Schein Medical, S.L.U. to expand its distribution of FebriDx® to Spain and Portugal. Henry Schein’s Medical business in Spain - which is part of Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of healthcare solutions to office-based dental and medical practitioners - will now imminently commence sales and marketing activities in these key markets. With clearance now granted for FebriDX by the US FDA, there is promising commercial interest in the device - and Henry Schein is an increasingly important part of the Company’s growing global distribution network. Click here to read the ASX release 👉 https://lnkd.in/g8h4_FHQ $LDX #LDX #FDA #medicaldevice #pointofcare  #invest #innovation #health #biotech #medtech #AMR

Download our case study to learn how #IQVIA #MedTech specialty reps brought in $245M in incremental revenue for a medical device manufacturer. https://bit.ly/49RD0eS

Medical device distributors operate in a unique realm between the customers and manufacturers of medical devices. Living in that nexus and aided by the vast array of products they manage, they can quickly identify trends in the marketplace and needs that aren’t being met by the manufacturers themselves. Because of this, many distributors choose to expand their operations to private labeling. This enables them to tailor products to specific market segments or customer needs, offering customization and product differentiation. If you’re a distributor looking to delve into private labeling there are some key questions to consider before making the leap: What are the regulatory requirements to make this transition? How does the FDA’s view of my establishment change? What systems and procedures do I need to implement my strategy? What are some pitfalls I’ll need to avoid? This article delves into some of the big questions about private labeling. https://wix.to/AMt2MQo #newblogpost https://wix.to/rGECbqR